Alberto J Montero

Summary

Affiliation: Medical University of South Carolina
Country: USA

Publications

  1. pmc Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review
    John Hayslip
    Hollings Cancer Center, Medical University of South Carolina, Clinical Sciences Building Room 903, PO Box 250635, Charleston, SC 29425, USA
    Mol Cancer 5:44. 2006
  2. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
  3. pmc Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)
    Mohamed L Salem
    Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    J Immunol 182:2030-40. 2009
  4. doi request reprint Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status
    Joan E Cunningham
    Hollings Cancer Center, Medical University of South Carolina, Charleston, 29425, USA
    Cancer Causes Control 21:399-409. 2010
  5. pmc Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA
    Cancer Immunol Immunother 57:563-72. 2008
  6. pmc Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Matthew A Beldner
    Division of Medical Oncology Hematology, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA
    BMC Cancer 7:231. 2007
  7. ncbi request reprint Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review
    Vinay Gudena
    Department of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Biol Ther 7:810-3. 2008
  8. pmc Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
    Claudia Marcela Diaz
    Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
    J Transl Med 11:62. 2013
  9. pmc Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    John Hayslip
    Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
    BMC Cancer 7:221. 2007
  10. ncbi request reprint Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma
    Amy Skorupa
    Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Biol Ther 6:1015-7. 2007

Collaborators

Detail Information

Publications11

  1. pmc Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review
    John Hayslip
    Hollings Cancer Center, Medical University of South Carolina, Clinical Sciences Building Room 903, PO Box 250635, Charleston, SC 29425, USA
    Mol Cancer 5:44. 2006
    ..Finally, reactivation of methylated tumor suppressor genes through the use of hypomethylating agents is a promising and novel approach to the treatment of indolent and transformed follicular lymphomas...
  2. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
    ..This information must be incorporated into the design of future trials exploring immune-based therapeutic strategies. Pharmacologic modulation of MDSC should also be tested in future clinical trials...
  3. pmc Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)
    Mohamed L Salem
    Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    J Immunol 182:2030-40. 2009
    ..In conclusion, our data show that CTX treatment induces, during the restoration phase, expansion of immature DCs, which are functional and can be exploited in vivo to foster more effective antitumor adoptive immunotherapy strategies...
  4. doi request reprint Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status
    Joan E Cunningham
    Hollings Cancer Center, Medical University of South Carolina, Charleston, 29425, USA
    Cancer Causes Control 21:399-409. 2010
    ..This approach also may aid in estimating the race-specific incidence rates of triple-negative breast cancer...
  5. pmc Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA
    Cancer Immunol Immunother 57:563-72. 2008
    ..Together, our results suggest that in vitro conditioning of naïve CD8+ T cells with IL-12 prior to ACT could significantly enhance their anti-tumor activity...
  6. pmc Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Matthew A Beldner
    Division of Medical Oncology Hematology, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA
    BMC Cancer 7:231. 2007
    ....
  7. ncbi request reprint Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review
    Vinay Gudena
    Department of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Biol Ther 7:810-3. 2008
    ..Studies are ongoing and the results are eagerly awaited regarding the responses to these medications and whether they can positively impact on the natural history of this disease...
  8. pmc Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
    Claudia Marcela Diaz
    Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
    J Transl Med 11:62. 2013
    ..We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV disease...
  9. pmc Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    John Hayslip
    Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
    BMC Cancer 7:221. 2007
    ..The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortezomib in combination with celecoxib in patients with advanced solid tumors...
  10. ncbi request reprint Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma
    Amy Skorupa
    Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Biol Ther 6:1015-7. 2007
    ..Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment...
  11. ncbi request reprint Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer
    Alberto J Montero
    Division of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina, USA
    Cancer Biol Ther 5:1494-501. 2006
    ..In conclusion, EGFR is hypermethylated and silenced in a subset of solid tumor cell lines and primary tumor specimens, and cotreatment with decitabine and gefitinib has an additive effect only in EGFR methylated breast cancer cell lines...